Treprostinil Drugs Market - High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of market
Treprostinil is an antihypertensive agent used to
treat patients with pulmonary arterial hypertension. It can also be used in the
treatment of Degos disease, an extremely rare disorder in which small and
medium sized arteries become blocked (occlusive arteriopathy), restricting the flow
of blood to affected areas.
Market Dynamics
High prevalence of pulmonary arterial hypertension
is expected to propel growth of the treprostinil drugs market. For instance,
according to the study, ‘High Geographic Prevalence of Pulmonary Artery
Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published
in February 2020, in the journal Pulmonary Circulation, the overall pulmonary
arterial hypertension incidence was 14 cases per million and the annual period
prevalence of pulmonary arterial hypertension was 93 cases per million.
Decline in new prescriptions for treprostinil-based
products is expected to hinder growth of the treprostinil drugs market. For
instance, United Therapeutics reported a decline in new prescriptions from the
company’s treprostinil-based products during the month of April 2020.
Comments
Post a Comment